Results 21 to 30 of about 61,856,371 (158)

Enfermedad de Gaucher en Argentina. Un informe del Registro Internacional de Gaucher y del Grupo Argentino de Diagnóstico y Tratamiento de la Enfermedad de Gaucher [PDF]

open access: yes, 2013
Fil: Guelbert, N. B. Universidad Nacional de Córdoba. Facultad de Ciencias Médicas. Centro de Estudios de las Metabolopatías Congénitas; Argentina.
Drelichman, G.   +26 more
core   +8 more sources

Frequency of rs1051338 and rs116928232 Variants in Individuals from Northwest Mexico [PDF]

open access: yesJournal of Clinical Laboratory Analysis, Volume 38, Issue 13-14, July 2024.
This study examines the frequency of two specific LIPA variants, rs1051338 and rs116928232, in 310 healthy Mexican mestizo individuals and the effects of these on protein structure by bioinformatic analysis. The results confirm the effects of this variants on LAL function and are consistent with existing data, underscoring the significance of this ...
Angélica Alejandra Hernández‐Orozco   +7 more
wiley   +2 more sources

Manifestaciones óseas de la enfermedad de Gaucher: A propósito de dos casos [PDF]

open access: yesAnales de Medicina Interna, 2004
La enfermedad de Gaucher es la enfermedad hereditaria de depósito lisosomal más frecuente. Se caracteriza por una deficiencia de la enzima glucocerebrosidasa que conduce a la acumulación de substrato en el interior de los lisosomas de los macrófagos. Se clasifica en tres tipos según exista afectación de sistema nervioso central (tipos 2 y 3) o no (tipo
Campo López,C.   +3 more
core   +6 more sources

P1690: NEUTROPHIL EXTRACELLULAR TRAP (NET) LEVELS IN COVID-19 PATIENTS [PDF]

open access: yesHemaSphere, 2022
L. López De Frutos   +8 more
doaj   +2 more sources

Gaucher disease and chronic myeloid leukemia: first reported patient receiving enzyme replacement and tyrosine kinase inhibitor therapies simultaneously [PDF]

open access: yesClinical Case Reports, Volume 6, Issue 5, Page 887-892, May 2018., 2018
Report a female diagnosed as type 1 Gaucher disease after a femoral pathologic fracture when she was 55 years old. Enzyme replacement therapy was started, and she achieved therapeutic goals. In 2015, a Ph’ CML with numerous pseudo‐Gaucher cells in bone marrow appears. BCR/ABL was not present at GD diagnosis.
MSoledad Noya   +5 more
wiley   +2 more sources

Twice weekly dosing with Sebelipase alfa (Kanuma®) rescues severely ill infants with Wolman disease [PDF]

open access: yesOrphanet Journal of Rare Diseases
Background Sebelipase alfa (Kanuma®) is approved for patients with Wolman disease (WD) at a dosage of 3–5 mg/kg once weekly. Survival rates in the second of two clinical trials was greater, despite recruiting more severely ill patients, probably related ...
María José de Castro   +17 more
doaj   +2 more sources

Manifestaciones esqueléticas de la enfermedad de Gaucher tipo 1 [PDF]

open access: yesRevista Médica Hondureña, 2008
La enfermedad de Gaucher tipo1 (EG1) es el trastorno lisosomal más frecuente observado en clínica médica. Es causado por un déficit congénito de la enzima glucocerebrosidasa. Se caracteriza por un proceso crónico, multisistémico y heterogéneo. El 80% de los pacientes presentan compromiso óseo: necrosis avascular, fracturas, deformidad en matraz de ...
Mastaglia, Silvina Rosana   +1 more
openaire   +4 more sources

Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

open access: yesMovement Disorders, Volume 38, Issue 2, Page 286-303, February 2023., 2023
Abstract Background As gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of
Eva‐Juliane Vollstedt   +306 more
wiley   +1 more source

CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 11, Page 1764-1777, November 2022., 2022
Abstract Background Neuroinflammation has been shown to be an important pathophysiological disease mechanism in frontotemporal dementia (FTD). This includes activation of microglia, a process that can be measured in life through assaying different glia‐derived biomarkers in cerebrospinal fluid. However, only a few studies so far have taken place in FTD,
Ione O. C. Woollacott   +152 more
wiley   +1 more source

Home - About - Disclaimer - Privacy